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Abstract
Background: The use of neonatal screening for cystic fibrosis is widely debated in the United
Kingdom and elsewhere, but the evidence available to inform policy is limited. This paper explores
the cost-effectiveness of adding screening for cystic fibrosis to an existing routine neonatal
screening programme for congenital hypothyroidism and phenylketonuria, under alternative
scenarios and assumptions.
Methods: The study is based on a decision model comparing screening to no screening in terms
of a number of outcome measures, including diagnosis of cystic fibrosis, life-time treatment costs,
life years and QALYs gained. The setting is a hypothetical UK health region without an existing
neonatal screening programme for cystic fibrosis.
Results: Under initial assumptions, neonatal screening (using an immunoreactive trypsin/DNA two
stage screening protocol) costs £5,387 per infant diagnosed, or £1.83 per infant screened (1998
costs). Neonatal screening for cystic fibrosis produces an incremental cost-effectiveness of £6,864
per QALY gained, in our base case scenario (an assumed benefit of a 6 month delay in the
emergence of symptoms). A difference of 11 months or more in the emergence of symptoms (and
mean survival) means neonatal screening is both less costly and produces better outcomes than no
screening.
Conclusion: Neonatal screening is expensive as a method of diagnosis. Neonatal screening may
be a cost-effective intervention if the hypothesised delays in the onset of symptoms are confirmed.
Implementing both antenatal and neonatal screening would undermine potential economic benefits,
since a reduction in the birth incidence of cystic fibrosis would reduce the cost-effectiveness of
neonatal screening.
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Background
Cystic fibrosis is an inherited disorder associated with
considerable morbidity and reduced life expectancy. The
UK birth prevalence is about 0.4 per 1,000, or 300 new
cases each year [1,2]. A recent report from the UK NHS
Health Technology Assessment Programme recom-
mended that antenatal screening for cystic fibrosis should
be offered routinely, and that "Health Authorities could
consider introducing neonatal screening" [3].
Antenatal screening aims to prevent affected births and
neonatal screening aims to improve prognosis by early
intervention. Studies of the effectiveness of neonatal
screening have measured short-term outcomes or are sub-
ject to statistical biases, including selection and lead-time
bias, and the use of historical controls [4-8]. Thus the abil-
ity of neonatal screening to alter long-term prognosis is
not proven, although there is limited circumstantial evi-
dence favouring a benefit [3].
All four existing economic evaluations of neonatal screen-
ing for cystic fibrosis are from the USA, and are ten or
more years old [9-12]. None used any measure of health
effect or performed extensive sensitivity analysis, and only
two of the studies compared screening to a do-nothing
alternative. Exclusion of the no-screening alternative
seems inappropriate, as the type and scale of the benefits
of cystic fibrosis screening remain uncertain.
Given the short-comings of these studies, and the lack of
full economic evaluations based on UK service and sur-
vival data, we aimed to compare the lifetime cost-effec-
tiveness of neonatal screening with no screening, under
different possible scenarios for survival with cystic fibro-
sis. We undertook this from the perspective of a hypothet-
ical UK Health Authority that has an existing routine
neonatal screening programme for congenital hypothy-
roidism and phenylketonuria but not for cystic fibrosis.
Methods
To allow a full exploration of the uncertainty surrounding
our cost-effectiveness estimates, they were created using a
decision tree, incorporating Markov processes to model
lifetime costs and quality of life [13]. We modelled a
screening programme using two-stage immunoreactive
trypsin combined with genetic testing strategy (Figure 1).
This model has replaced two stage immuno-reactive
trypsin tests in a number of programmes internationally,
and is the commonest protocol used in programmes start-
ing after 1990 [3].
The disease progression was modelled as a Markov proc-
ess. All cases are 'born' into the pre-symptomatic health-
state. Then, each year, there is a given probability of mov-
ing into the symptomatic disease state, then into the
severe irreversible lung disease-state, and finally death
(with the probabilities of moving into the last two states
changing over time). These states broadly correspond with
the stages of disease described in paediatrics, and also
reflect thresholds between different therapy regimes [14].
The model excluded those cases (15% in the base case sce-
nario) diagnosed at or shortly after birth, for example by
meconium ileus or family history, since these infants
would have received the same prognosis and treatment
under both strategies. Under the "no screening" strategy
infants would be diagnosed with cystic fibrosis sympto-
matically (late diagnosis). Under the screening strategy
most cystic fibrosis cases would be detected by screening
(early diagnosis), with the remainder – the false negatives
– experiencing the disease under late diagnosis
assumptions.
The putative benefit of early diagnosis through neonatal
screening was modelled as a difference in the annual tran-
sition probability of remaining pre-symptomatic. In the
initial model this probability was 69% for those diag-
nosed through screening (compared with 59% for those
diagnosed symptomatically) resulting in a delay of the
emergence of symptoms of 6 months.
The decision analysis model uses three types of data;
probability data, cost data, and quality of life estimates for
the three health states: these data were obtained from a
variety of different sources as referenced in Tables 1, 2 and
3.
Probability data
The transition probabilities in the Markov model were
estimated to achieve age-specific survival rates and other
estimated parameters, in three alternative scenarios; based
on conservative, balanced and optimistic assumptions of
recent UK age-specific survival data supplied by one of the
authors, PL (Figure 2 and Table 3). The annual transition
probabilities that best predicted these calibration data
were (for the balanced scenario, 'late diagnosis'): from
asymptomatic to symptomatic, 0.491 per year (with the
remainder all staying asymptomatic); symptomatic to
severe irreversible lung disease, 0.0064 increasing expo-
nentially according the accumulated years with symptoms
(with hazard rates derived from Dodge et al. 1997); severe
irreversible lung disease to death, 0.09 increasing accord-
ing to the number of years spent in the severe irreversible
disease stage. (Excel spreadsheets available on request
from the first author, NS). These allowable transitions
effectively make the simplifying assumptions that all peo-
ple with CF ultimately die of CF-related respiratory symp-
toms, and that all pass through both the symptomatic and
severe irreversible lung disease stages before they die.Cost Effectiveness and Resource Allocation 2005, 3:8 http://www.resource-allocation.com/content/3/1/8
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Decision tree for no screening and neonatal screening strategies for cystic fibrosis Figure 1
Decision tree for no screening and neonatal screening strategies for cystic fibrosis.
Strategy - No neonatal screening
Strategy - Neonatal screening
1 - immuno-reactive trypsin + genetic testing
* = life with cystic fibrosis diagnosed "late" by presentation of symptoms
** = life with cystic fibrosis diagnosed "early" by screening
*** = represent screening false positives
1 For simplicity in our model confirmatory sweat tests were included as part of the
genetic analysis stage, and with assumed test sensitivity and specificity of 100%.
Birth
Life without
cystic fibrosis
Life with cystic
fibrosis*
Birth
Low
High
Life without
Cystic fibrosis
False negative -
Life with
cystic fibrosis*
Blood
IRT
Blood
DNA
Life without
cystic fibrosis
False negative -
Life with
cystic fibrosis*
Life with
cystic fibrosis**
Life without
cystic fibrosis***
No
mutations
Homozygous
Life with
cystic fibrosis**
Heterozygous
+ sweat testCost Effectiveness and Resource Allocation 2005, 3:8 http://www.resource-allocation.com/content/3/1/8
Page 4 of 11
(page number not for citation purposes)
Cost data
The following screening costs were the included in the
model: counselling time required by midwives to obtain
consent for testing, immunoreactive trypsin test, DNA
analysis and sweat chloride test. Other costs related to
obtaining the blood spot and feedback of results by health
visitors, were assumed to be sunk in the existing neonatal
screening programmes for phenylketonuria and congeni-
tal hypothyroidism.
We assume the addition of cystic fibrosis screening does
not increase refusals or insufficient blood samples and
that 100% of the neonatal population would be covered
by the programme [15]. Time for genetic counselling for
carriers identified by the screening programme were
excluded from the model.
The pre-diagnosis healthcare costs for children with late
diagnosis (no-screening) was estimated via an audit of the
clinical notes of 25 children with cystic fibrosis, attaching
unit costs to derive the mean cost of pre-diagnosis care
(Table 2).
Disease state-specific costs of treatment were derived from
the cost of care of 161 patients at a large UK cystic fibrosis
unit during 1996 which were based on annual medical
costs for patients at different age groups and at different
disease stages (Table 2) [14]. Only CF-related health care
costs are included, including any costs incurred during
additional years of life added by early diagnosis. All cost
data was adjusted for inflation at 5% to the reference year
of 1998. Future treatment costs in the model were dis-
counted at 6% per year [16].
Effectiveness data
It has been shown [17,18] that forced expiratory volume
in one second (FEV1) is associated with quality of life, as
measured by the Quality of Well-Being Scale (a prefer-
ence-based quality of life instrument used in economic
evaluation) [19], as well as with morbidity and mortality
[20,21]. These Quality of Well-Being scores remain the
only preference-based estimates of health-related quality
of life in people with CF. On the basis of these findings, a
quality of life value was assigned to each Markov state
(Table 3) and multiplied by survival time in the same state
to produce quality-adjusted life expectancy. Future QALYs
were discounted in the model (2% in base case analysis)
[16].
A wide range of one-way, and selected multi-way sensitiv-
ity analyses were undertaken. The sensitivity analyses
reported here are those that either (a) had a significant
impact on the incremental cost-effectiveness ratio, or (b)
related to parameters for which reliable published esti-
mates were not available (e.g. QALYs per year of life lived
with CF symptoms or severe irreversible symptoms, and
the cost of pre-diagnosis care for those diagnosed sympto-
matically). Microsoft Excel© (version 5.0) spreadsheet soft-
ware was used to develop the model and conduct the
analyses – the models are available on request from the
lead author.
Results
Our base case assumptions gave an estimated cost per
diagnosed infant of £5,387 (or £1.83 per infant screened),
compared with an estimated cost per case diagnosed clin-
ically of £936. £4,020 (75%) of this cost is due to those
components of the screening process that are carried out
for every infant screened i.e. the immunoreactive trypsin
test, and the explanation of the test by midwives (Table 4).
Table 1: Model parameters, data sources and values used in the model.
Probabilities
Variable Base case value Range used in sensitivity analysis
Incidence of cystic fibrosis [2] 0.0004 0.00067 – 0.00029
% diagnosed at birth (MI & family history) [39] 0.15 0.10 – 0.40
IRT test sensitivity [40] 0.9 0.99
IRT test specificity [40] 0.995 0.999
DNA test: % of mutations detected [40] 0.88 0.85 – 0.95
DNA test sensitivity [40] 0.9856 0.9975
DNA test specificitya 1.0
Increased annual transition probability of remaining without symptoms (in early-diagnosed 
cases)b
10% 10 – 40%
a It is assumed that there are no false positives (from the combined DNA and sweat tests), because all test results that are either homozygous or 
heterozygous for cystic fibrosis mutations, are confirmed using sweat tests.
b Assumed effect of early diagnosisCost Effectiveness and Resource Allocation 2005, 3:8 http://www.resource-allocation.com/content/3/1/8
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Table 2: Model parameters, data sources and values used in the model.
Costs (all inflated to reference year 1998)
Variable Base case value Range used in sensitivity analysis
Costs of screening
Additional time to explain test (survey by NS) £0.40a (2.1 mins) £0 – £1.44 (0 – 7.6 mins)
Obtaining and transport of blood sampleb £0
IRT test (Bradley DM – pers. comm.) £0.97 £0.50 – £1.50
DNA test (Bradley DM – pers. comm.) £79.48 £40.00 – £120.00
Sweat test (Walker S – pers. comm) £29.40 £15.00 – £45.00
Administration and feedback of resultsc £0
Cost of pre-diagnosis care in unscreened group (audit by NS)
Presumed GP visits (mean number of visits)d £14.77 (1.27) £11.63 – £46.52 (1 – 4)
Outpatient attendances (mean number)e £129.07 (1.47) £0 – £263.40 (0 – 3)
Inpatient admissions (mean number of 
admissions and days per admission)f
£792.55 (0.87) (3.0 days) £0 – £1821.96 (0–2)
Costs of treatment per year in health state by age group g14
Presymptomatic 0–5 £2,950
6–10 £3,995
11–15 £4,570
> 16  £4,275
Symptomatic 0–5 £15,241
6–10 £15,704
11–15 £19,247
>16 £19,291
Severe irreversible symptoms 0–5 £28,722
6–10 £30,692
11–15 £37,224
>16 £37,388
a Whitley Councils for the Health Services Pay Scales – 1/4/98 (Nursing and Midwifery) + 16% on-costs = £11.33/hour
bc Assumed to be a shared cost with existing screening programmes
d The Government's Expenditures Plans 1996–97, Cost/GP consultation = £11.63
e Annual financial returns for NHS Trusts 97/98, Cost//paediatric outpatient attendance = £87.80
f Annual financial returns for NHS Trusts 97/98, Cost//patient-day in paediatric ward) = £303.66
g Hospital staff, overhead and capital costs are included in the average cost per day for inpatient stays and the average cost of outpatient attendance. 
Drug costs were derived from the monthly index of medical specialities (MIMMS) and do not include individual hospital discount arrangements 
(1996 costs inflated to 1998).
Table 3: Model parameters, data sources and values used in the model.
Utility values of symptom states
Variable Base case value Range used in sensitivity analysis
Asymptomatic – latea 0.95 0.90
Asymptomatic – earlyb 0.95 0.90
Symptoms (FEV1 – 60%, range 40%–80%) [17,41] 0.75 0.65 – 0.90
Severe irreversible symptoms (FEV1 – 30%, range 20–40%) [17,41] 0.68 0.58 – 0.78
a utility value to reflect "taking regular medication or staying on a prescribed health diet for health reasons" derived from community surveys.
b arbitrary utility weight to reflect the probable repeated visits to GP with undiagnosed CFCost Effectiveness and Resource Allocation 2005, 3:8 http://www.resource-allocation.com/content/3/1/8
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If the explanation to parents of cystic fibrosis screening
could be incorporated within existing screening arrange-
ments, the average cost per diagnosed infant would fall by
22% to £4,220. Conversely, if explaining cystic fibrosis
screening cannot be incorporated in the existing process,
but instead commits midwives to seven and a half min-
utes more time [22], then the cost per diagnosed infant
rises to £8,443. Even with highly optimistic assumptions
regarding the specificity and sensitivity of both screening
tests the mean cost of diagnosis by screening falls by only
a fifth, to £4,351. The cost of diagnosis is more sensitive
to the incidence of the disease, and the proportion of cases
detected at birth (Figure 3).
Neonatal screening for cystic fibrosis produced (under
base case assumptions) an average of 0.36 additional
QALYs per life with cystic fibrosis at an additional cost of
£2,895 (or a cost per QALY gained of £6,864) (Figure 4).
A delay in the emergence of symptoms, or an increase in
survival of 11 months or more (i.e. an increase in the
probability of remaining without symptoms of 15 per-
centage points or more), compared to unscreened infants,
Survival curves under conservative, balanced and optimistic assumptions Figure 2
Survival curves under conservative, balanced and optimistic assumptions.
Table 4: Components of the average cost of diagnosis by screening
Cost component Mean cost of diagnosis per 
infant screened (£)
Mean cost of diagnosis per 
infant diagnosed (£)
Cost to average Health 
Authoritya per year (£)
Midwife time explaining test 0.40 1,167 2,380
IRT tests (kits, & overheads) 0.97 2,853 5,820
DNA tests (kits, labour & overheads) 0.42 1,240 2,530
Confirmatory sweat tests 0.01 22 44
Pre-diagnosis care of false negatives 0.04 106 216
Total average cost 1.83 5,387 10,990
a Health Authority with a population of 500,000 and assumed crude birth rate of 12 per 1000 population per year.
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would produce lower costs and better outcomes than no
screening (Figure 4). A wide range of different quality of
life estimates for the two disease states produce negligible
changes in the cost-effectiveness ratio. This is because in
this model the main effect of early diagnosis is to delay the
emergence of symptoms, but the progression of disease
thereafter is the same under the late and early diagnosis
assumptions.
If pre-diagnosis care (of those diagnosed symptomati-
cally) does not involve admission to hospital then the
incremental cost-effectiveness ratio falls by 32% to £4,640
per QALY. Under any of the survival models if annual
treatment costs are increased by as much as 20% the cost
per QALY gained only increases by 11%. Also, as life
expectancy increases so does the incremental cost-effec-
tiveness of neonatal screening (Table 5).
Discussion
As a method of diagnosis neonatal screening is relatively
expensive. At £5,387 per diagnosed infant, our estimate of
the cost of diagnosis is similar to a previous (1997) esti-
mate of £6,400 [23]. Compared to no screening, neonatal
screening for cystic fibrosis (under base case assumptions)
produces an incremental cost-effectiveness of £6,864 per
QALY gained.
There are a number of key assumptions and potential lim-
itations to this study. Firstly, in relation to the model
structure, we have simplified the representation of cystic
fibrosis. However our representation of the disease – as
three health states within a Markov model – makes best
use of available knowledge. Also, we have assumed that
the effect of early diagnosis is a delay in the emergence of
respiratory symptoms after prophylactic treatment (but,
with the subsequent treatment cost and quality of life in
those states being the same for screened and unscreened
infants). This choice was made in the absence of evidence
to suggest other ways of modelling the effect of early diag-
nosis. Unfortunately, while recent trials or observational
studies have shown that early (neonatal) diagnosis and
treatment results in improvements in nutritional status,
Cost of diagnosis (£) by screening assuming different disease incidence and different proportions diagnosed at birth by other  means Figure 3
Cost of diagnosis (£) by screening assuming different disease incidence and different proportions diagnosed at birth by other 
means.
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Incremental cost-effectiveness (£/QALY) of neonatal screening for cystic fibrosis compared with no screening, assuming differ- ent cost discount rates and assumed effects of preventive therapy Figure 4
Incremental cost-effectiveness (£/QALY) of neonatal screening for cystic fibrosis compared with no screening, assuming differ-
ent cost discount rates and assumed effects of preventive therapy.
Table 5: Cost-effectiveness of screening compared to no screening under various survival scenarios
Scenario: Conservative survivala Balanced survivala Optimistic survivala
Model parameter:
% surviving to age 16 90% 95% 97%
% surviving to age 30 72% 84% 90%
% surviving to age 50 30% 45% 55%
Median survival (years) 41 48 52
Mean survival (years) 39.4 45.8 49.9
Mean years spent:
before symptoms emerge 1.0 1.0 1.0
with symptoms 32.3 38.7 42.8
in severe irreversible stage 6.1 6.1 6.1
Incremental C/E ratio (£/QALY) £7,474 £6,864 £6,532
a Under late diagnosis assumptions
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height and weight, and cognitive functioning, evidence
about the long-term impact of early diagnosis on lung
function (and therefore mortality) remains uncertain [24-
28].
The model assumes that cystic fibrosis in infants is a rela-
tively homogeneous condition. However, the spectrum of
cases ranges from neonates that are severely affected, to
cases who live a normal life undiagnosed until adulthood.
It is possible that the more severe but asymptomatic cases
would benefit most from early diagnosis. Those with
milder forms of the disease would be diagnosed later
under the no-screening strategy and would have their age
at diagnosis advanced most under screening. The data in
existing population-based data sets are insufficient to
investigate this issue (PL – author), so this point has been
ignored.
Our survival estimates are based on the most recent and
reliable age-specific survival data. As yet there is a limited
understanding of the interactions of cystic fibrosis with
the normal ageing process. Recent clinical experience indi-
cates that potentially life-shortening complications such
as diabetes mellitis and liver disease may become more
frequent with advancing age, so projections based on
experience of younger people may be inaccurate [2,29].
Although it is possible that recent improvements in sur-
vival may be confounded by the introduction of neonatal
screening in some areas in the 1970s and 1980s, regional
variations in mortality do not show this (PL – author).
Further, using Quality of Well-Being (QWB) scores as a
basis for weighting the quality of extra years survived may
not provide a true indicator of relative preferences for
being in these different health states. However, it remains
the only health-related quality of life instrument that has
been used widely in people with cystic fibrosis [30].
Overall, as far as presently available data allow, the model
structure and data inputs would satisfy most of the criteria
that are recommended in current guidelines for good
practice in decision analytic modelling [31]. External val-
idation of the model is more problematic since valid data
about either the long-term health effects of screening or
the future survival of people with cystic fibrosis does not
yet exist. Due to the absence of published data on the dis-
tributions underlying the means of most parameters our
sensitivity analysis is restricted to one-way and two-way
sensitivity analysis. Future modelling of these policy
choices should attempt to use data that allow more prob-
abilistic sensitivity analysis to be conducted, but with the
proviso that model structure (or methodological) uncer-
tainty can only be explored using traditional 'non-proba-
bilistic' methods.
A number of costs, which may in theory are important
have been omitted, either because of the complexity of
deriving estimates, or their probable minimal effect on
the main findings. The omitted costs are; the potential
effects of distress or reassurance related to screening [32],
self- and lay-care costs (for example, therapy provided by
parents or by the patients themselves), unrelated health
care costs and savings resulting from increasing life
expectancy (for example, additional years of economically
productive life); the costs of genetic counselling (gener-
ated by the identification of carriers); and the treatment
option of heart-lung transplantation.
The omission of genetic counselling costs was partly
because the benefits of such counselling would be diffi-
cult to quantify. Existing evidence also shows that, of the
small number of carriers that will be identified, only a
minority take up counselling and the cost of providing
this counselling is small in relation to total screening costs
[33,34]. With regard to heart-lung transplantation, this
treatment option is currently only available to a relatively
small proportion of people with cystic fibrosis. Even if this
changes there is no reason to assume that the costs, bene-
fits or availability would be different for those diagnosed
at birth by screening and those diagnosed later sympto-
matically [35-39].
With regard to the generalisability of the findings, this
study has most relevance to the UK context: it employs
cost estimates based on NHS care and the survival esti-
mates are derived from the UK National Cystic Fibrosis
Survey [1]. Although comparisons with other studies are
difficult; the costs of care at the Leeds unit (average annual
cost of £10,567 [14]) from which our data are derived
were comparable with another UK study [40].
Although a number of alternative screening protocols are
being used in the UK and world-wide, they all employ an
IRT test as the initial screening stage for all neonates. Our
analysis shows that it is the cost of this initial stage, carried
out on all infants, which most affects the cost-effective-
ness ratio, and also that differences in the performance of
the screening protocol produce only minor changes.
Therefore, it is unlikely that substantially different results
would be obtained with alternative protocols.
We have shown that, in the absence of antenatal screen-
ing, neonatal screening costs of £6,864 per QALY gained,
based on an assumed benefit of six months average delay
in the onset of symptoms, and that it would be less costly
and more beneficial if the benefit were shown to be 11
months or more. As further evidence becomes available it
will be clearer if this threshold can be realised. The model
used here could be adapted to reflect new effectiveness
data, associations between genotype and phenotype, newCost Effectiveness and Resource Allocation 2005, 3:8 http://www.resource-allocation.com/content/3/1/8
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treatments for cystic fibrosis as they become available;
and local information concerning populations or services.
Comparisons of cost per affected pregnancy identified by
antenatal screening with averted treatment costs are gen-
erally favourable [3]. However, these studies give no value
to a life lived with cystic fibrosis. They also assume around
90% uptake of prenatal diagnosis and effectively universal
termination of affected pregnancies. This contrasts with
surveys of affected individuals and close family members
which suggest that only about half find termination of an
affected pregnancy acceptable [41-43]. Changes in public
attitudes about prenatal diagnosis and termination might
further affect the economic value of antenatal screening.
In the UK policy context Murray et al. recommended both
that antenatal screening should be offered routinely and
that health authorities 'could consider' introducing neo-
natal screening. They also suggest that routine antenatal
screening would reduce the birth prevalence of cystic
fibrosis by between 43% and 49% [3]. According to our
analysis, by halving the birth prevalence of the disease, the
cost per QALY gained for neonatal screening would
increase to £19,543. With this lower prevalence at birth,
early diagnosis would have to delay the emergence of
symptoms on average by 20 months or more for neonatal
screening to be less costly and more beneficial.
In 1998 in the UK, up to a quarter of the population were
covered by six regional programmes of neonatal screening
for cystic fibrosis and we are aware of only one scheme
which provides routine antenatal screening (in Edin-
burgh) [3]. Any economic evaluation of antenatal
screening compared with neonatal screening is impossi-
ble as the strategies have such different aims. Fundamen-
tally, the benefits are not comparable: in antenatal
screening the aim is to allow reproductive choice, includ-
ing the option to terminate affected pregnancies, whereas
neonatal screening primarily aims to improve the length
and quality of life of sufferers. Economic evaluations of
antenatal screening have therefore tended to give no value
to a life with cystic fibrosis, and instead attribute financial
savings to lives with cystic fibrosis avoided.
In conclusion, according to the scenarios explored here, as
long as the birth incidence of cystic fibrosis remains sta-
ble, there is no reason for existing neonatal screening pro-
grammes to be discontinued on cost-effectiveness
grounds. Although UK Health Authorities wanting to
introduce neonatal screening may want to see more relia-
ble evidence of the health benefits of early diagnosis
before making a decision, this evidence is now beginning
to emerge, especially from the Wisconsin trial [44]. It has
prompted the (UK) NHS National Screening Committee
to implement a national neonatal screening programme
for England (Scotland introduced theirs in 2003). As this
programme is rolled out to different regions from April
2005 (see http://www.newbornscreening-bloods
pot.org.uk) more reliable data on how early diagnosis
alters lung function and long-term survival will become
available, and could be used to update this cost-effective-
ness analysis.
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